Stocktwits on MSN

Eli Lilly stock rises after late-stage data shows longer survival with breast cancer drug

The study showed benefits beyond survival, including slower disease progression in certain patient groups. ・Combining the ...
Nasdaq

Lilly to present new clinical data for Verzenio (abemaciclib) and multiple novel pipeline programs at the 2025 European Society for Medical Oncology (ESMO) Annual Meeting

Primary overall survival analysis from the Phase 3 monarchE study of Verzenio (abemaciclib) in HR+HER2-, node-positive, high-risk early breast cancer to be presented as a late-breaking oral ...
PMLive

Lilly announces new study data on Inluriyo in metastatic breast cancer

Follow-up results from the phase 3 EMBER-3 study showed that, as a monotherapy, Inluriyo demonstrated a 38% reduction in the ...
Seeking Alpha

Lilly's Verzenio® (abemaciclib) prolonged survival in HR+, HER2-, high-risk early breast cancer with two years of treatment

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...
Asianet Newsable on MSN

Eli Lilly unveils new data showing longer survival with breast cancer drug in late-stage study

The updated study showed Imlunestrant improved survival and reduced the risk of disease progression or death in patients with ...